Actinium Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATNM NYSE American 2830 www.actiniumpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - Nov 18th, 2024 1:00 pm
Actinium: Q3 Earnings Snapshot - Nov 15th, 2024 12:02 am
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - Nov 4th, 2024 12:30 pm
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Oct 18th, 2024 4:00 pm
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Sep 23rd, 2024 8:52 am
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - Sep 20th, 2024 12:00 pm
Actinium: Q2 Earnings Snapshot - Aug 5th, 2024 10:59 pm
Sector Update: Health Care Stocks Fall in Afternoon Trading - Aug 5th, 2024 6:10 pm
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. - Aug 5th, 2024 11:00 am
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications - Aug 1st, 2024 12:00 pm
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University - Jul 25th, 2024 12:45 pm
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US - Jul 25th, 2024 11:30 am
3 Under-$10 Biotech Stocks That Could Make You Rich - Jul 11th, 2024 6:23 pm
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns - Jul 2nd, 2024 9:05 pm
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? - Jun 20th, 2024 1:40 pm
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions - Jun 18th, 2024 12:45 pm
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) - Jun 17th, 2024 12:45 pm
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress - Jun 17th, 2024 12:00 pm
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial - Jun 14th, 2024 12:30 pm
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - Jun 11th, 2024 12:30 pm